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Wilson disease (WD) is an autosomal recessive disorder that is caused by the toxic accumulation of copper (Cu) in the liver. The
ATP7B gene, which is mutated in WD, encodes a multitransmembrane domain adenosine triphosphatase that trafﬁcs from the
trans-Golgi network to the canalicular area of hepatocytes, where it facilitates excretion of excess Cu into the bile. Several ATP7B
mutations, includingH1069Q andR778L that are two of themost frequent variants, result in protein products, which, although still
functional, remain in the endoplasmic reticulum. Thus, they fail to reach Cu excretion sites, resulting in the toxic buildup of Cu in
the liver of WD patients. Therefore, correcting the location of these mutants by leading them to the appropriate functional sites in
the cell should restore Cu excretion and would be beneﬁcial to help large cohorts of WD patients. However, molecular targets for
correction of endoplasmic reticulum-retained ATP7B mutants remain elusive. Here, we show that expression of the most frequent
ATP7B mutant, H1069Q, activates p38 and c-Jun N-terminal kinase signaling pathways, which favor the rapid degradation of the
mutant. Suppression of these pathways with RNA interference or speciﬁc chemical inhibitors results in the substantial rescue of
ATP7BH1069Q (as well as that of several other WD-causing mutants) from the endoplasmic reticulum to the trans-Golgi network
compartment, in recovery of its Cu-dependent trafﬁcking, and in reduction of intracellular Cu levels. Conclusion:Our ﬁndings indi-
cate p38 and c-JunN-terminal kinase as intriguing targets for correction ofWD-causingmutants and, hence, as potential candidates,
which could be evaluated for the development of novel therapeutic strategies to combatWD. (HEPATOLOGY 2016;63:1842-1859)
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The liver is essential for the maintenance ofcopper (Cu) homeostasis as it plays a centralrole in the excretion of this essential, yet toxic
metal. This is highlighted by Wilson disease (WD), an
autosomal recessive disorder in which biliary excretion
of Cu is severely impaired, causing the toxic accumula-
tion of the metal in the liver.(1,2)
The ATP7B gene (defective in WD) encodes a
Cu-transporting P-type adenosine triphosphatase that
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GFP, green ﬂuorescent protein; GO, gene ontology; ICP-MS, inductively coupled plasma mass spectrometry; JNK, c-Jun N-terminal kinase; MAPK,
mitogen-activated protein kinase; MS, mass spectrometry; PM, plasma membrane; ROS, reactive oxygen species; TGN, trans-Golgi network; WD,
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pumps cytosolic Cu across cellular membranes, using
the energy derived from adenosine triphosphate hydro-
lysis (Fig. 1A). Increased Cu levels prompt ATP7B to
trafﬁc from the Golgi to compartments that are involved
in Cu excretion.(3,4) WD-associated mutations affect
the intracellular trafﬁcking of ATP7B to the canalicular
area of hepatocytes and/or the protein’s ability to trans-
fer Cu across the membrane.(3,4) This results in the fail-
ure of hepatocytes to remove excess Cu into the bile
and, thus, leads to the accumulation of the metal, which
causes cell death and Cu accumulation in extrahepatic
tissues. Therefore, clinical features of WD often include
hepatic abnormalities, neurological defects, and psychi-
atric symptoms. When left untreated, liver failure may
result in death.(1,2)
WD treatment may be successfully approached with
zinc (Zn) salts and Cu-chelating agents. However, these
treatments do have serious toxicities.(2,5) Moreover, about
one-third of WD patients do not respond efﬁciently
either to Zn or to Cu chelators.(6) All considered, devel-
oping novel WD treatment strategies has become an
important goal. When approaching therapeutic solutions,
properties of WD-causing mutants should be carefully
considered. The most frequent ATP7B mutations (Fig.
1A), H1069Q (40%-75% in the white patient popula-
tion) and R778L (10%-40% of Asian patients), result in
ATP7B proteins with signiﬁcant residual activities,(7-9)
which, however, are strongly retained in the endoplasmic
reticulum (ER).(10) Notably, many other WD-causing
ATP7B mutants with substantial Cu-translocating activ-
ity undergo complete or partial arrest in the ER.(11) Thus,
although potentially able to transport Cu, these ATP7B
mutants cannot reach the Cu excretion sites to remove
excess Cu from hepatocytes. ER retention of such
ATP7B mutants occurs due to their misfolding(10,11) and
increased aggregation(12) and, hence, their failure to fulﬁll
the requirements of the ER quality control machinery. As
a result, the cellular proteostatic network recognizes
ATP7B mutants as defective and directs them toward
the ER-associated protein degradation (ERAD) path-
way.(9) Therefore, identifying molecular targets for the
recovery of partially or fully active ATP7B mutants from
the ER to the appropriate functional compartment(s)
would be beneﬁcial for the majority ofWD patients.
Here, we demonstrate, using both systems biology
and classical approaches, that the degradation of the
most frequent ATP7BH1069Q mutant is under the con-
trol of the stress kinases p38 and c-Jun N-terminal
kinase (JNK). Suppressing both p38 and JNK resulted
in the efﬁcient correction of the mutant, thus allowing it
to be transported from the ER to the trans-Golgi net-
work (TGN), and supported its Cu-induced trafﬁcking
to the post-Golgi vesicles and canalicular surface of
polarized hepatic cells. As a consequence, treatments
with p38 or JNK inhibitors reduced Cu accumulation in
cells expressing ATP7BH1069Q and attenuated degrada-
tion of the mutant due to its improved sorting from the
ER into the secretory pathway. Our ﬁndings suggest
that p38 and JNK signaling pathways may serve as
attractive targets for the correction of WD-causing
mutants and could be explored for the development of
therapeutic approaches that counteract WD.
Materials and Methods
ANTIBODIES, REAGENTS, AND
DNAS
Antibodies against phospho-p38, phospho-JNK,
phospho-extracellular signal-regulated kinase (ERK),
p38, JNK, and ERK were from Cell Signaling Tech-
nology (Beverly, MA). The DNAs of ATP7A and its
mutants were already reported.(13) DNAs of ﬂag-
tagged MKK3, MKK4, MKK6, and MKK7 were
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obtained from Addgene (Cambridge MA). To obtain
the R778L, D765N, L776V, A874V, and L1083F
mutants of ATP7B, the phosphorylated enhanced
green ﬂuorescent protein (GFP) C1-ATP7B construct
was used as a template and site-directed mutagenesis
was performed according to the manufacturer’s
instructions using the QuickChange kit (Stratagene,
La Jolla, CA). Other reagents, antibodies, DNAs, and
viruses have been reported.(14)
CELL CULTURE
HeLa and HepG2 cells and primary mouse hepato-
cytes were grown in Dulbecco’s modiﬁed Eagle’s
medium supplemented with fetal calf serum 10%
(decomplemented for HepG2 cells), L-glutamine, and
penicillin/streptomycin.
IMMUNOPRECIPITATION AND
MASS SPECTROMETRIC
ANALYSIS
To compare interactomes of ATP7BH1069Q-GFP
or ATP7BWT-GFP, the tagged proteins were immu-
noprecipitated from cell lysates with the anti-GFP
antibody. Pull-downs were fractionated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis, and
the protein bands were digested with trypsin. Peptide
mixtures were analyzed by nano-chromatography tan-
dem mass spectrometry (MS/MS) on a CHIP MS Ion
Trap XCT Ultra (Agilent Technologies, Palo Alto,
CA). Peptide analysis was performed using data-
dependent acquisition of one MS scan (mass range
400-2000 m/z) followed by MS/MS scans of the three
most abundant ions in each MS scan. Raw data from
nano liquid chromatography-MS/MS analyses were
employed to query a nonredundant protein database
using in-house MASCOT software (Matrix Science,
Boston, MA).
MICROARRAY ANALYSIS
To identify the effects of ATP7BH1069Q expression
on the transcriptome, total RNA was extracted from
HepG2 cells (expressing either ATP7BH1069Q-GFP
or ATP7BWT-GFP) and hybridized on Affymetrix
GeneChips. All of the raw microarray data were for-
matted for the Gene Expression Omnibus to comply
with Minimum Information About a Microarray
Experiment and Microarray Gene Expression Data-
base group standards (Gene Expression Omnibus
number GSE51818). Microarray analyses were carried
out with R, a free software environment. Genes that
passed all ﬁltering criteria were entered into the
DAVID Gene Functional Annotation Tool. The gene
ontology (GO) options GOTERM_BP_ALL and
GOTERM_MF_ALL were selected, and a functional
annotation chart was generated. A maximum P value
of 0.05 was chosen to select only the signiﬁcant
categories.
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FIG. 1. Expression of the ATP7BH1069Q mutant is associated with activation of p38 and JNK signaling pathways. (A) Schematic
structure of ATP7B. Black circles show N-terminal metal binding domains. Numbers indicate transmembrane helices. The domains
which regulate adenosine triphosphatase activity are indicated in italic with D residue for catalytic phosphorylation. Yellow stars indi-
cate the position of the most frequent WD-causing mutations, H1069Q and R778L. (B) HepG2 cells were infected with Ad-
ATP7BWT-GFP or Ad-ATP7BH1069Q-GFP and prepared for microarray analysis (see Materials and Methods). Genes that were dif-
ferently expressed in cells expressing ATP7BH1069Q were analyzed for GO enrichment. The pie diagram shows the GO categories
that were enriched among the altered genes in ATP7BH1069Q-expressing cells, as opposed to cells expressing ATP7BWT (see also
Supporting Table S1). Genes involved in the regulation of apoptosis constituted the largest group of genes whose expression was
altered by the ATP7BH1069Q mutant. (C) HepG2 cells were infected with Ad-ATP7BWT-GFP or Ad-ATP7BH1069Q-GFP and ana-
lyzed with western blot. Phosphorylated forms of p38 or JNK increased in cells expressing the ATP7BH1069Q mutant, while overall
amounts of p38 or JNK remained similar in wild type-expressing and mutant-expressing cells. (D) Putative interactors of ATP7BWT
and ATP7BH1069Q were identiﬁed using a proteomics approach (see Materials and Methods). The diagram shows the number of
interactors that were speciﬁc for ATP7BWT or for ATP7BH1069Q, as well as the number of common interactors. GO analysis revealed
ATP7BWT interactors to be enriched in proteins belonging to membrane trafﬁcking categories, while mutant-speciﬁc interactors were
enriched in proteins involved in ER-associated protein quality control and degradation. (E) HepG2 cells expressing ATP7BH1069Q
were transfected with activators of p38 (MKK3 and MKK6) or JNK (MKK4 and MKK7). Western blot (see also quantiﬁcation
graph) revealed a decrease in ATP7BH1069Q levels in cells expressing p38 or JNK activators. Na/K-adenosine triphosphatase was used
as input control. The modest decrease in ATP7BH1069Q in cells transfected with MKK4 is due to lower overexpression of MKK4 in
comparison to other MKKs. (F) The schematic drawing shows a vicious circle that is generated by expression of the ATP7BH1069Q
mutant, which leads to activation of ER quality control and degradation of ATP7BH1069Q. As a consequence of ATP7BH1069Q loss,
ROS increase and stimulate p38 and JNK signaling, which triggers further retention and degradation of the mutant in the ER, pre-
venting it from being exported to the secretory pathway. Abbreviations: ADP, adenosine diphosphate; ATP, adenosine triphosphate;
P-, phosphorylated.
HEPATOLOGY, Vol. 63, No. 6, 2016 CHESI ET AL.
1845
STATISTICAL ANALYSIS
Data were expressed as mean values 6 standard
deviation. The Student t test was used to compare dif-
ferences between two groups by GraphPad Prism 6
software (GraphPad Prism Inc., San Diego, CA).
Statistically signiﬁcant differences between them are
indicated by the following: *P < 0.05, **P < 0.01, and
***P < 0.001.
OTHER METHODS
Adenoviral and vesicular stomatitis viral infection,
DNA transfection, RNA interference, quantitative
polymerase chain reaction, ﬂuorescent microscopy,
immuno-electron microscopy (EM), inductively
coupled plasma mass spectrometry (ICP-MS), and
western blot analysis were done as reported.(14) For
details see the Supporting Information.
Results
EXPRESSION OF THE ATP7BH1069Q
MUTANT INDUCES ACTIVATION
OF p38 AND JNK
We used unbiased approaches to understand which
molecular pathway could be targeted to correct
mutants causing WD. We ﬁrst sought to determine
how ATP7BH1069Q mutant expression affects the tran-
scriptome of hepatic cells. Comparison of microarrays
from ATP7BH1069Q-expressing and ATP7BWT-
expressing cells revealed 626 differently expressed
genes (GSE51818). GO analysis of these hits indi-
cated enrichment in genes that regulate cell death and
response to stress (Fig. 1B; Supporting Table S1). Sev-
eral of these genes (SQSTM1, TXNIP, IL6R,
FOSL1, MAP2K6, and NET1) have been reported to
operate in mitogen-activated protein kinase (MAPK)
signaling pathways mediated by two proapoptotic
stress kinases, p38 and JNK.(15) This might be linked
to WD pathogenesis because reactive oxygen species
(ROS) accumulating in WD(3) can stimulate the activ-
ity of p38 and JNK.(15-18) Indeed, several ROS-
sensitive genes (SOD2, MSRA, TP53I3) were up-
regulated in ATP7BH1069Q-expressing cells. This
prompted us to investigate whether the activity of these
kinases rises upon ATP7BH1069Q expression. Western
blot analysis revealed that phosphorylated p38 and
JNK increased signiﬁcantly in cells expressing the
mutant (Fig. 1C), indicating that both kinases were
activated. In the meantime the MAPK kinase/ERK
pathway of the MAPK signaling cascade was not acti-
vated as the levels of phosphorylated ERK remained
unaltered in mutant-expressing cells (Supporting Fig.
S1A).
We also compared the interactomes of ATP7BWT and
ATP7BH1069Q. Proteomics analysis revealed 31
ATP7BWT-speciﬁc and 51 ATP7BH1069Q-speciﬁc inter-
actors (Supporting Tables S2 and S3). GO analysis indi-
cated that speciﬁc binding partners of ATP7BWT were
enriched in “intracellular trafﬁcking” proteins (Fig. 1D).
In contrast, the ATP7BH1069Q interactome contained
numerous proteins belonging to the “unfolded protein
binding,” “proteasome,” and “ubiquitination” GO catego-
ries (Fig. 1D). These differences are in line with an
enhanced association of the mutant with the components
of the ER-associated quality control machinery, resulting
in ER retention of the mutant.(9,10) Notably, speciﬁc
MAPK pathways, which include p38 and JNK, have
recently been shown to affect proteostasis of proteins such
as cystic ﬁbrosis transmembrane conductance regulator
(CFTR)(19) and to regulate the expression of ER quality
control/degradation genes.(15) We thus examined whether
activation of p38 and JNK might lead to the accelerated
degradation of ATP7BH1069Q. Indeed, overexpression of
the upstream activators of p38 (MKK3 and MKK6) or
JNK (MKK4 and MKK7) reduced ATP7BH1069Q levels,
indicating increased mutant degradation (Fig. 1E).
On the whole, the above observations indicate that
induction of p38 and JNK may be triggered by
ATP7BH1069Q expression. This activation, in turn, may
promote ER retention and degradation of the mutant,
an increase in ROS levels (due to Cu accumulation),
and further perturbation of ER proteostasis, generating
a vicious circle (Fig. 1F). In this context, p38 and JNK
represent regulatory centerpieces and potential drug-
gable targets to prevent ER retention of the mutant
and, hence, to rescue its localization and function.
SUPPRESSION OF p38 AND JNK
RESCUES APPROPRIATE
LOCALIZATION AND
TRAFFICKING OF THE
ATP7BH1069Q MUTANT
To test whether deactivating the p38 and JNK path-
ways facilitates ATP7BH1069Q export from the ER, we
suppressed the activity of p38 and JNK ﬁrst by using
speciﬁc chemical inhibitors, SB202190 (SB90) and
SP600125 (SP125), and then by RNA interference. We
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initially evaluated the impact of p38/JNK-speciﬁc inhib-
itors and small interfering RNAs in HeLa cells, given
that silencing of the genes of interest can be easily
achieved in this cell type. In cells treated with the Cu
chelator bathocuproine disulfonate (BCS), ATP7BWT
was mainly detected over the Golgi membranes, while
ATP7BH1069Q remained in the ER (Fig. 2A, upper
row). Neither p38 and JNK inhibitor (added for 24
hours) affected ATP7BWT (Supporting Fig. S2A), but
both reduced ATP7BH1069Q within the ER and
improved the delivery of the mutant to the Golgi (Fig.
2A[upper row],B). The correction of ATP7BH1069Q
localization was remarkably effective even at quite low
concentrations (Supporting Fig. S2B). Interestingly, the
combination of p38 and JNK inhibitors did not further
increase mutant relocation from the ER to the Golgi
(Supporting Fig. S3), suggesting that the two inhibitors
target similar molecular pathways for correction of
ATP7BH1069Q. In control experiments the ERK inhibi-
tor failed to correct the mutant from the ER to the
Golgi (Supporting Fig. S1B). This indicates that only
p38 and JNK branches of the MAPK signaling cascade
are involved in mutant retention in the ER. Impor-
tantly, acute suppression of p38 and JNK did not impact
ER export of ATP7BH1069Q (Supporting Fig. S4).
Therefore, inhibitors apparently act through the tran-
scriptional regulation of quality control and/or trafﬁck-
ing genes rather than by reducing the direct
phosphorylation of the mutant or components of its
trafﬁcking machinery.
Next, we investigated whether the inhibitors rescue
Cu-responsive trafﬁcking of ATP7BH1069Q. CuSO4
addition induced redistribution of ATP7BWT from
the TGN to the plasma membrane (PM) and periph-
eral vesicular structures but failed to induce
ATP7BH1069Q relocation from the ER (Fig. 2A, lower
row). Instead, when corrected by p38/JNK antagonists,
ATP7BH1069Q efﬁciently moved from the Golgi to the
PM and vesicles in response to elevated Cu (Fig.
2A,C).
The above results were conﬁrmed by biochemistry
and EM. Western blot exhibited reduced amounts of
ATP7BH1069Q in the PM subcellular fractions in com-
parison to ATP7BWT, while both p38 and JNK inhibi-
tors signiﬁcantly increased quantities of the mutant
delivered to the cell surface (Supporting Fig. S5). In
turn, EM revealed ATP7BH1069Q mainly over the ER
membrane proﬁles, while cells incubated with p38
antagonists contained the mutant in TGN membranes
(Fig. 2D). In response to CuSO4 treatment inhibitor-
treated cells delivered ATP7BH1069Q from the TGN to
the cell surface and endosome/lysosome-like “vesicles”
(Fig. 2D), which normally receive ATP7BWT upon Cu
overload.(14) Thus, it turns out that, once corrected to
the Golgi by p38/JNK inhibitors, the mutant reacts to
increasing Cu by trafﬁcking to Cu excretion sites, just as
ATP7BWT does.
To further verify the above conclusions, we silenced
different isoforms of p38 (MAPK11-MAPK14) and
JNK (MAPK8-MAPK10) in cells expressing
ATP7BH1069Q (Fig. 3A). Both reduction in ER reten-
tion and recovery of Golgi and vesicle targeting of the
mutant were detected after depletion of MAPK8,
MAPK11, and MAPK14 (Fig. 3B,C). In addition, we
sought to suppress MAP3K11, the upstream activator
of both p38 and JNK,(20) to evaluate whether this treat-
ment improved ATP7BH1069Q recovery from the ER.
MAP3K11 has been reported to effectively correct
D508-CFTR.(19) Indeed, depletion of MAP3K11
resulted in strong reduction of ATP7BH1069Q in the
ER (Fig. 3B,C).
We next investigated whether inhibitors of p38 or
JNK overcome the ER retention of other ATP7B
mutants with residual activity.(7,11) Correction was
achieved for D765N, L776V, and R778L mutants but
not for A874V and L1083F variants (Fig. 4). Mean-
while, p38 and JNK antagonists failed to correct
ATP7A mutants with post-Golgi trafﬁcking defects
(Fig. 5), indicating that inhibitors act mainly at the ER
level. In summary, our observations suggest that sup-
pressing p38 or JNK allows various ATP7B mutants to
escape ER retention in a manner that depends on the
type of mutation.
p38 AND JNK INHIBITORS
RESCUE ATP7BH1069Q
TRAFFICKING AND TARGETING
IN HEPATIC CELLS
As a further step, we tested whether suppressing p38
and JNK is efﬁcient at rescuing the mutant in WD-
relevant cellular systems such as HepG2 cells and primary
hepatocytes.(21) In HepG2 cells, ATP7BWT moved from
the Golgi to the vesicles and cell membrane in response
to Cu (Fig. 6A), while most of the ATP7BH1069Q was
arrested in the ER, regardless of changes in Cu concen-
trations (Fig. 6A). However, incubation with either p38
inhibitor or JNK inhibitor allowed signiﬁcant amounts of
ATP7BH1069Q to reach the Golgi and to be transported
toward the PM and associated vesicles in response to Cu
overload (Fig. 6A,B). Moreover, the ATP7BH1069Q
mutant was targeted to the appropriate canalicular surface
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domain in polarized HepG2 cells (Supporting Fig. S6).
Importantly, primary hepatocytes exhibited a similar
response to p38 inhibitor and JNK inhibitor, which res-
cued ATP7BH1069Q from the ER and allowed it to trafﬁc
toward Golgi and post-Golgi Cu excretion sites (Fig.
6C,D). Therefore, hepatic cells tend to deliver the
ATP7B mutant to the right compartments upon sup-
pression of p38 and JNK signaling pathways.
CORRECTION OF THE
ATP7BH1069Q MUTANT WITH p38
OR JNK INHIBITORS
FACILITATES CU EXCRETION
We reasoned that correcting ATP7BH1069Q from the
ER to the appropriate Cu excretion sites should reduce
the total amount of intracellular Cu. To test this
hypothesis we used ICP-MS. ICP-MS measurements
revealed higher concentrations of the metal in cells
expressing ATP7BH1069Q, while treatment with p38 or
JNK inhibitor signiﬁcantly reduced intracellular Cu lev-
els (Fig. 7A).
To further support these ﬁndings, we used copper
sensor 3 (CS3), which becomes ﬂuorescent in the pres-
ence of bioavailable Cu.(22) We found low CS3 signal
in cells expressing ATP7BWT, whereas CS3 ﬂuores-
cence was higher in mutant-expressing cells (Fig. 7B).
p38 and JNK inhibitors signiﬁcantly decreased CS3
signal in cells expressing ATP7BH1069Q (Fig. 7B,C).
More importantly, reduction in CS3 ﬂuorescence (and
hence in Cu levels) correlated with the amount of
ATP7BH1069Q expressed in inhibitor-treated cells
(Supporting Fig. S7). Collectively, the above ﬁndings
indicate that correcting the mutant to the appropriate
compartments with p38/JNK antagonists allows the
cells to eliminate excess Cu.
p38 AND JNK INHIBITORS
REDUCE DEGRADATION OF
ATP7BH1069Q BY IMPROVING
MUTANT SORTING INTO THE
SECRETORY PATHWAY
In the ER the failure of misfolded protein to pass the
quality control check directs such a protein to degrada-
tion.(23) Therefore, we analyzed whether p38 or JNK
inhibitors counteract ATP7BH1069Q degradation. We
found that the ATP7BH1069Q protein product increased
in response to p38 and MAPK inhibition (Fig. 8A),
while the levels of its messenger RNA remained the
same in treated cells (not shown). This indicated that
suppressing p38 and JNK attenuates degradation of the
mutant. To support this conclusion we treated cells with
cycloheximide and found that p38 and JNK inhibitors
signiﬁcantly slowed down the kinetics of mutant turn-
over (Fig. 8B,C). Thus, our results suggest that suppres-
sion of the p38 and JNK pathways allows
ATP7BH1069Q to circumvent ERAD.
How do p38 and JNK antagonists suppress
ATP7BH1069Q degradation? The ﬁrst possibility is
that they directly inhibit the ERAD components that
comprise the proteasome.(23) Being protected from
ERAD, aberrant ATP7B molecules would reside in
the ER longer and, therefore, may have a higher
chance to be incorporated into carriers that transport
them from the ER to the Golgi. To test whether this
is the case, we treated ATP7BH1069Q-expressing cells
with the proteasome inhibitor MG132. MG132
increased ATP7BH1069Q levels (Fig. 8D) but failed to
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FIG. 2. Inhibitors of p38 and JNK correct localization and trafﬁcking of ATP7BH1069Q mutant. (A) HeLa cells were infected with
Ad-ATP7BWT-GFP or Ad-ATP7BH1069Q-GFP, incubated overnight with 200 lM BCS, and ﬁxed or incubated for an additional 2
hours with 100 lM CuSO4. In response to Cu, ATP7B
WT (left column) trafﬁcs from the Golgi (arrowheads in upper panel) to the
PM and vesicle (arrows in lower panel), while ATP7BH1069Q (second column) is retained within the ER under both low-Cu and
high-Cu conditions. The p38 inhibitor SB202190 (5 mM) or the JNK inhibitor SP600125 (2 mM) was added to the cells 24 hours
before ﬁxation (as indicated in the corresponding panels). Fixed cells were further labeled for TGN46 and visualized under a confocal
microscope. Both p38 and JNK inhibitors corrected ATP7BH1069Q from the ER to the Golgi (arrowheads in upper panels) under
low-Cu conditions and to the PM and vesicles (arrows in lower panels) in high-Cu conditions. (B) Cells were treated with BCS and
drugs as shown in (A). Fluorescence of ATP7B signal in the Golgi (average 6 standard deviation, n 5 40 cells) was quantiﬁed and
normalized to total cell ﬂuorescence. Both inhibitors caused an increase of ATP7BH1069Q signal in the Golgi region. (C) Cells were
treated as in (A). The percentage of cells (average 6 standard deviation, n 5 10 ﬁelds) with an ATP7B signal in the ER, Golgi, or
PM/vesicles was calculated. Both p38 and JNK inhibitors reduced the percentage of cells exhibiting ATP7BH1069Q in the ER and
increased the number of cells in which ATP7B was corrected to the Golgi under low-Cu conditions and to the PM and vesicles upon
Cu stimulation. (D) Cells were treated as in (A) and prepared for immuno-EM (see Materials and Methods). Arrows indicate
ATP7BH1069Q in the ER. Arrowheads show ATP7BWT or ATP7BH1069Q in the Golgi. Empty arrows indicate ATP7BWT or
ATP7BH1069Q signal at the PM, while asterisks label ATP7B-positive multivesicular body-like vesicles. Scale bars 5 5 lm (A) and
260 nm (D). Abbreviations: inh, inhibitor; WT, wild type.
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FIG. 3. Silencing of several p38 and JNK isoforms corrects localization and trafﬁcking of the ATP7BH1069Q mutant. (A) HeLa cells
were incubated with small interfering RNA, which targets speciﬁc genes (indicated in graph) belonging to the p38 and JNK pathways.
The efﬁciency of silencing for each gene was evaluated by quantitative reverse-transcription polymerase chain reaction and expressed as
fold-change (average 6 standard deviation, n 5 3 experiments) after normalization to messenger RNA levels of the same gene in con-
trol cells (treated with scramble small interfering RNA). (B) HeLa cells were silenced for different p38 and JNK isoforms as in (A),
then infected with Ad-ATP7BH1069Q-GFP and incubated for 2 hours with 100 lM CuSO4. Fixed cells were then labeled for
TGN46 and visualized under a confocal microscope. Silencing of MAPK8, MAPK11, MAPK14, or MAP3K11 showed the rescue of
ATP7BH1069Q from the ER and its movement to the post-Golgi vesicles (arrows) and PM. (C) Cells were treated as in (B). The per-
centage of cells (average 6 standard deviation, n 5 10 ﬁelds) with ATP7BH1069Q signal in the ER was calculated. RNA interference
of MAPK8, MAPK11, MAPK14, and MAP3K11 reduced the percentage of cells exhibiting ATP7BH1069Q in the ER. Scale bar 5
4.7 lm (B). Abbreviations: mRNA, messenger RNA; si, small interfering.
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FIG. 4. Impact of p38 and JNK inhibitors on localization of ER-retained ATP7B mutants. (A) HeLa cells were transfected with dif-
ferent ATP7B mutants (indicated in each panel), then treated for 24 hours with either p38 or JNK inhibitor and exposed to 100 lM
CuSO4 for 2 hours. Cells were then ﬁxed, labeled for TGN46, and visualized under a confocal microscope. All mutants exhibited
clear ER patterns in cells that were not treated with inhibitors. Incubation with either p38 or JNK inhibitor allowed R778L, D765N,
and L776V mutants of ATP7B to be transported to the Golgi, post-Golgi vesicles (arrows), and PM. In contrast, inhibitors did not
recover either L1083F or A874V mutants of ATP7B from the ER (two bottom rows). (B) Cells were treated as in (A). The percent-
age of cells (average 6 standard deviation, n 5 10 ﬁelds) with ATP7B signal in the ER was calculated for each mutant. p38 and
JNK inhibitors reduced the percentage of cells that exhibited R778L, D765N, and L776V in the ER. Scale bar 5 5 lm (A). Abbrevi-
ation: inh, inhibitor.
                                                                                                                                      
HEPATOLOGY, Vol. 63, No. 6, 2016 CHESI ET AL.
1851
overcome mutant retention in the ER (Fig. 8E). This
indicates that inhibitor-mediated recovery of
ATP7BH1069Q from the ER does not involve ERAD
components.
Therefore, ATP7BH1069Q may be protected from
degradation as a result of accelerated trafﬁcking from
the ER. To verify this we ﬁrst observed whether p38
and JNK inhibitors accelerated overall trafﬁcking rates
in the secretory pathway. This was not the case as the
trafﬁcking kinetics of the generic cargo protein VSVG
was not altered in SB90-treated or SP125-treated cells
(Supporting Fig. S8).
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FIG. 5. p38 and JNK inhibitors do not rescue post-Golgi trafﬁcking of ATP7A mutants. HeLa cells were transfected with either
ATP7AWT (A), ATP7AA1362D (B), or ATP7AL873R (C) mutant. Then, cells were exposed to a 200 lM treatment with BCS (-Cu)
and ﬁxed directly or incubated with 100 lM CuSO4 for an additional 2 hours (1Cu). p38 or JNK inhibitors were added (as indicated
in B and C) for 24 hours prior to ﬁxation. Fixed cells were labeled for TGN46 and visualized under a confocal microscope. (A)
ATP7AWT moved from the Golgi (top panel) to the PM (bottom panel) after Cu increase. (B) ATP7BA1362D mutant remained asso-
ciated with TGN46 under both low-Cu and high-Cu conditions (left column). Neither p38 nor JNK inhibitors allowed the mutant to
be transported from the Golgi to the PM in response to increasing Cu (middle and right columns). (C) The ATP7AL873R mutant
remained distributed over the PM, independently of the Cu levels (left column). Incubation with p38 or JNK inhibitors did not cor-
rect the mutant from the PM to the Golgi (middle and right columns), even when Cu levels were low (top row). Scale bar 5 4.8 lm
(A-C). Abbreviation: inh, inhibitor.
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FIG. 6
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We further hypothesized that the suppression of
p38 and JNK might speciﬁcally accelerate trafﬁcking
rates of the ATP7BH1069Q mutant from the ER to the
Golgi. To test this hypothesis we used selective photo-
bleaching, which allowed us to analyze protein
exchange between different compartments in live
cells.(24) We bleached ATP7BWT-GFP or
ATP7BH1069Q-GFP in the Golgi region and observed
how the material from the ER recovered GFP signal
in the bleached area (Fig. 8F). Recovery of
ATP7BH1069Q-GFP ﬂuorescence in the Golgi reached
the plateau with the same dynamics (t1/2  1 min) in
both control and inhibitor-treated cells (Fig. 8G).
However, the amount of ATP7BH1069Q-GFP that
reappeared within the Golgi over the same time inter-
val was markedly higher in cells incubated with p38 or
JNK inhibitor (Fig. 8F,G). These observations indicate
that suppressing p38 and JNK does not shorten the
time needed for a given ATP7BH1069Q molecule to be
transported from the ER to the Golgi. Instead, p38
and JNK antagonists allow a higher number of
ATP7BH1069Q molecules to be sorted from the ER
and transported to the Golgi during this interval.
To further support this point we evaluated the distri-
bution of ATP7BH1069Q at the ER export sites (ERES)
using immuno-EM. ERES contain coated buds (Fig.
8H-J, arrowheads) emerging from the ER cisternae and
associated vesicular-tubular membranes (Fig. 8H-J,
empty arrows) that carry newly synthetized proteins to
the Golgi. Normally, membrane proteins directed into
the secretory pathway (like ATP7BWT) undergo enrich-
ment in the ERES membranes (Fig. 8H, empty arrows)
over regular ER cisternae.(25) Such concentration in
ERES was not detected for ATP7BH1069Q. Indeed,
ATP7BH1069Q-associated gold particles decorated
mainly ER cisternae (Fig. 8I, arrows) and were scarce in
the coated buds (Fig. 8I, arrowhead) and neighboring
vesicles (Fig. 8I, empty arrows). Incubation with either
p38 or JNK inhibitor increased the density of
ATP7BH1069Q in the ERES buds (Fig. 8J, arrowhead)
and vesicular proﬁles (Fig. 8J, empty arrows) and
reduced ATP7BH1069Q signal in ER cisternae (Fig. 8J,
arrows; quantiﬁcation in Fig. 8H). This trend indicates
that inhibiting p38 and JNK facilitates sorting of
ATP7BH1069Q from the ER into nascent Golgi-
directed transport intermediates.
Discussion
The main ﬁnding in this study is that p38 and JNK
play an important role in WD by promoting retention
and degradation of the ATP7BH1069Q mutant in the
ER. Thus, suppression of p38 and JNK allows
ATP7BH1069Q to reach the post-Golgi vesicles and
the apical surface in hepatocytes, from where it can
contribute to the removal of excess Cu from the cell.
As a consequence, treatment with p38 or JNK inhibi-
tor reduces Cu accumulation in cells expressing
ATP7BH1069Q. Thus, p38 and JNK represent attrac-
tive targets for correction of the ATP7B mutant local-
ization and function and could be considered for the
development of novel therapeutic strategies to counter-
act WD.
A large proportion of WD-causing ATP7B muta-
tions result in a protein product that is still able to
pump Cu but remains retained within the ER and
undergoes accelerated degradation. Therefore, a thera-
peutic strategy that can target the proteostasis of these
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FIG. 6. Suppression of p38 and JNK corrects localization and trafﬁcking of ATP7BH1069Q mutant in hepatic cells. (A) HepG2 cells
were infected with Ad-ATP7BWT-GFP or Ad-ATP7BH1069Q-GFP, incubated overnight with 200 lM BCS, and ﬁxed or incubated
for an additional 2 hours with 100 lM CuSO4. In response to Cu, ATP7B
WT (left column) trafﬁcs from the Golgi (arrowheads in
upper panels) to the PM and vesicles (arrows in lower panels), while ATP7BH1069Q (second column) is retained in the ER under
both low-Cu and high-Cu conditions. p38 or JNK inhibitors were added to the cells 24 hours before ﬁxation (as indicated in the cor-
responding panels). Fixed cells were then labeled for TGN46 and visualized under a confocal microscope. Both p38 and JNK inhibi-
tors corrected ATP7BH1069Q from the ER to the Golgi (arrowheads in upper panels) under low-Cu conditions and to the PM and
vesicles (arrows in lower panels) upon Cu exposure. (B) Cells were treated as in (A). The percentage of cells (average 6 standard devi-
ation, n 5 10 ﬁelds) with ATP7B signal in the ER, Golgi, or PM/vesicles was calculated. Both p38 and JNK inhibitors reduced the
percentage of cells exhibiting ATP7BH1069Q in the ER independently from the Cu levels and increased the number of cells in which
ATP7B was corrected to the Golgi under low-Cu conditions and to the PM and vesicles upon Cu stimulation. (C) Primary hepato-
cytes isolated from mouse liver cells were infected with Ad-ATP7BWT-GFP or Ad-ATP7BH1069Q-GFP and then incubated with
100 lM CuSO4 for 2 hours. p38 or JNK inhibitors were added to the cells 24 hours before ﬁxation (as indicated in the corresponding
panels). Fixed cells were then labeled for giantin and visualized under a confocal microscope. Both p38 and JNK inhibitors corrected
ATP7BH1069Q from the ER to the PM and vesicles (arrows). (D) Primary hepatocytes were treated as in (C). The percentage of cells
(average 6 standard deviation, n 5 10 ﬁelds) with ATP7B signal in the ER, Golgi, or PM/vesicles was calculated. Both p38 and
JNK inhibitors reduced the percentage of cells exhibiting ATP7BH1069Q in the ER and increased the number of cells in which
ATP7B was corrected to the PM and vesicles upon Cu stimulation. Scale bars 5 5 lm (A) and 5.3 lm (C). Abbreviation: inh,
inhibitor.
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ATP7B mutants to reduce their degradation and to
improve their folding and export would be beneﬁcial
for the large cohort of WD patients.
In recent years, several attempts have been made in
this direction, with the use of correctors such as cur-
cumin and phenylbutyrate.(9) The rationale for using
these drugs is that they are effective at rescuing mis-
folded CFTR or lysosomal enzymes,(26,27) which
result in cystic ﬁbrosis and lysosomal storage diseases,
respectively. These drugs were shown to reduce the
degradation of several ER-retained mutants of
ATP7B.(9) Whether and how these correctors rescue
the appropriate localization of these ATP7B mutants
and, therefore, recover the ability of these aberrant
ATP7B proteins to eliminate Cu remains to be
demonstrated.
Several proteins have also been reported to modulate
the degradation of the ATP7B mutants and/or their
retention in the ER. These include COMMD1,(28)
clusterin,(29) and CRYAB.(12) However, these proteins
do not belong to the “druggable” category; thus, their
potential for the development of drugs to cure WD
remains questionable. Instead, both p38 and JNK rep-
resent bona ﬁde druggable targets, and their inhibitors
show high efﬁciency at rescuing several of these patho-
genic ATP7B variants. Their ability to recover
ATP7BH1069Q trafﬁcking in primary hepatocytes indi-
cates potential efﬁcacy in the hepatic tissue. This prop-
erty of p38 and JNK inhibitors is really important for
therapy because the number of active compounds
which are effective in immortalized cell lines frequently
fail to provide the same beneﬁcial impact in primary
cells or animals.(30) Unfortunately an animal model
that recapitulates ATP7BH1069Q mutation remains to
be developed. Therefore, evaluation of the inhibitor
efﬁciency in vivo represents a further challenging and
important goal.
Of note, the therapeutic potential of some p38 and
JNK antagonists has been explored for the treatment of
different disorders. Some p38 and JNK inhibitors have
entered phase 2 clinical studies for other disorders (Clini-
calTrials.gov identiﬁers NCT00316771, NCT00303563,
NCT00383188, NCT00620685, NCT00395577,
NCT00205478, NCT00390845, NCT00570752,
NCT01630252).(31) Thus, in theory the passage of
such p38 and JNK inhibitors into clinical use for WD
might be rapid as their toxicity level has been reported
to be relatively low(32) and may be further decreased
through speciﬁc delivery using ligands of the asialogly-
coprotein receptor.(33)
Which molecular mechanisms operate behind the
correction of the ATP7BH1069Q mutant? As we have
demonstrated, inhibition of p38 and JNK manifests
two main phenomena: a reduction in ATP7BH1069Q
degradation and an improved ATP7BH1069Q delivery
to the Golgi apparatus and to the post-Golgi compart-
ments. It turns out that a reduction in the degradation
of ATP7BH1069Q occurs as a consequence of increas-
ingly efﬁcient sorting of ATP7BH1069Q into the secre-
tory pathway. Indeed, photo-bleaching experiments
and immuno-EM indicate that p38 and JNK inhibi-
tors facilitate ATP7B mutant sorting from the ER
into the secretory pathway at the level of the ER exit
sites, while overall membrane trafﬁcking rates remain
unchanged.
Therefore, corrections of ATP7BH1069Q from the
ER into the secretory route probably arise through mod-
ulation of the proteostatic network, which improves the
ability of ATP7BH1069Q to be captured by the export
machinery in inhibitor-treated cells. ATP7BH1069Q
interactome exhibits a signiﬁcant enrichment in compo-
nents of ER quality control and ERAD. Thus, an
excessive amount of quality control proteins that bind
the mutant may prevent its transition from the ER to
the secretory pathway. Such a chaperone-mediated ER
trap was reported for the CFTR mutant.(34) The inhibi-
tors of p38 and JNK might reduce the amounts of qual-
ity control proteins that bind the ATP7B mutant and in
this way allow ATP7BH1069Q to escape into the secre-
tory pathway.
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FIG. 7. Inhibitors of p38 and JNK reduce Cu levels in cells expressing ATP7BH1069Q mutant. (A) HepG2 cells were infected with
Ad-ATP7BWT-GFP or Ad-ATP7BH1069Q-GFP and incubated with p38 or JNK inhibitor. CuSO4 at 100 lM concentration was
added to the cells for the last 2 hours of incubation with the inhibitors. The cells were examined by ICP-MS (see Materials and
Methods), which revealed an increase in normalized intracellular Cu levels (average 6 standard deviation, n 5 3 experiments) in
ATP7BH1069Q-expressing cells. Both p38 and JNK inhibitors reduced Cu levels in ATP7BH1069Q-expressing cells. (B) HepG2 cells
were infected with Ad-ATP7BWT-GFP or Ad-ATP7BH1069Q-GFP, incubated for 2 hours with 100 lM CuSO4, and loaded with
CS3 before ﬁxation. p38 or JNK inhibitors were added to the cells 24 hours before ﬁxation (as indicated in the corresponding panels).
Confocal microscopic images show CS3 ﬂuorescence in red (top row), in white (middle row), and in false color scale (bottom row).
Cells expressing ATP7BH1069Q exhibited higher CS3 signals than cells expressing ATP7BWT, while both p38 and JNK inhibitors
decreased CS3 ﬂuorescence in ATP7BH1069Q-expressing cells. (C) Quantiﬁcation revealed an increase in CS3 ﬂuorescence (average 6
standard deviation, n 5 10 ﬁelds) in cells expressing ATP7BH1069Q and a decrease of CS3 signal upon incubation with either p38 or
JNK inhibitor. Scale bar 5 14 lm (C). Abbreviations: AU, arbitrary units; inh, inhibitor; WT, wild type.
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Alternatively, inhibition of p38 and JNK may result
in the up-regulation of some chaperones that are nega-
tively regulated by these stress kinases. Thus, up-
regulation of such chaperones could improve mutant
folding and stability in cells treated with p38 or JNK
antagonists. We have shown that the CRYAB chaper-
one signiﬁcantly facilitates ATP7BH1069Q exit from
the ER.(12) Its activity and expression appear to be
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FIG. 8
                                                                                                                                      
HEPATOLOGY, Vol. 63, No. 6, 2016 CHESI ET AL.
1857
regulated by p38(35) and, therefore, might also be
modulated by p38 inhibition. It remains to be investi-
gated whether p38 antagonists can induce CRYAB
up-regulation in hepatocytes that express ATP7B
mutants.
Although p38 and JNK inhibitors were effective at
correcting several ER-retained ATP7B variants, they
did not rescue a few other ATP7B mutants from the
ER. Interestingly, mutations in the same domain (like
ATP7BH1069Q and ATP7BL1083F) are differently sen-
sitive to p38 and JNK inhibitors. This indicates that
p38-dependent and JNK-dependent machineries have
a certain level of speciﬁcity and that inhibiting them
does not seem to threaten the global quality-control
processes at the level of the ER. On the other hand,
p38 and JNK inhibitors also rescue some, but not all,
ER-retained mutants of other membrane proteins,
such as CFTR and P-glycoprotein.(19) Therefore, these
p38 and JNK inhibitors might modulate speciﬁc
mechanisms involved in the recognition of common
(or similar) protein-folding defects.
In conclusion, p38 and JNK signaling pathways may
serve as attractive targets to counteract WD by rescuing
ER-retained ATP7B mutants. It remains to be estab-
lished to what extent suppression of these pathways
would be able to prevent toxic Cu accumulation in
model animals or patients carrying corresponding
ATP7B mutations. On the other hand, the impact of
p38 and JNK antagonists on the key components of pro-
teostatic networks requires further detailed investigation.
This may expand the use of kinase inhibitors to correc-
tion of other ER-retained pathogenic mutants and,
hence, to open new avenues for therapeutic strategies to
combat disorders that are caused by protein misfolding.
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